CareDx, Inc (NASDAQ:CDNA) Director Sells $125,000.00 in Stock

CareDx, Inc (NASDAQ:CDNA) Director Peter Maag sold 5,000 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the director now owns 330,024 shares in the company, valued at $8,250,600. This represents a 1.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

CareDx Stock Performance

NASDAQ:CDNA traded down $0.68 during trading hours on Tuesday, reaching $24.96. The company had a trading volume of 548,186 shares, compared to its average volume of 795,245. The stock has a 50-day moving average of $25.51 and a two-hundred day moving average of $22.67. CareDx, Inc has a one year low of $7.42 and a one year high of $34.84.

CareDx (NASDAQ:CDNA) last announced its earnings results on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. The company had revenue of $82.88 million during the quarter, compared to the consensus estimate of $80.04 million. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company’s revenue was up 23.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.43) earnings per share. As a group, analysts predict that CareDx, Inc will post -0.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. The Goldman Sachs Group upped their target price on CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. HC Wainwright reissued a “neutral” rating on shares of CareDx in a research report on Tuesday, October 22nd. BTIG Research reduced their price objective on shares of CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company began coverage on shares of CareDx in a research report on Tuesday, August 27th. They set an “underweight” rating and a $28.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. According to MarketBeat.com, CareDx presently has an average rating of “Moderate Buy” and a consensus price target of $29.60.

Institutional Trading of CareDx

Hedge funds have recently added to or reduced their stakes in the business. Quarry LP acquired a new position in CareDx in the third quarter valued at about $27,000. Harvest Fund Management Co. Ltd bought a new stake in CareDx during the 3rd quarter worth approximately $52,000. GAMMA Investing LLC raised its holdings in CareDx by 1,021.8% during the 2nd quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after buying an additional 2,013 shares during the period. KBC Group NV acquired a new position in shares of CareDx in the third quarter valued at approximately $99,000. Finally, nVerses Capital LLC raised its holdings in shares of CareDx by 175.0% during the third quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock worth $103,000 after acquiring an additional 2,100 shares during the period.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.